FibroGen (NASDAQ:FGEN) Announces Quarterly Earnings Results

FibroGen (NASDAQ:FGEN) announced its earnings results on Tuesday. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.09, Zacks reports. The company had revenue of $50.64 million for the quarter, compared to analyst estimates of $33.00 million. During the same quarter last year, the business posted ($0.65) earnings per share.

FibroGen Stock Down 4.2 %

Shares of FibroGen stock traded down $0.02 during trading on Thursday, reaching $0.44. The company’s stock had a trading volume of 2,089,256 shares, compared to its average volume of 2,676,570. The business’s 50-day moving average price is $0.99 and its 200-day moving average price is $1.43. The firm has a market cap of $43.85 million, a PE ratio of -0.18 and a beta of 0.71. FibroGen has a 52 week low of $0.33 and a 52 week high of $2.93.

Analyst Ratings Changes

Separately, William Blair reiterated a “market perform” rating on shares of FibroGen in a report on Monday, June 3rd.

Insider Activity

In other FibroGen news, insider Deyaa Adib bought 22,123 shares of FibroGen stock in a transaction dated Wednesday, June 12th. The stock was bought at an average price of $1.17 per share, with a total value of $25,883.91. Following the completion of the transaction, the insider now owns 82,123 shares in the company, valued at approximately $96,083.91. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.98% of the stock is currently owned by company insiders.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.